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Abstract 
 
Background: The majority of patients with chronic kidney disease are diagnosed 
and monitored in primary care. Glomerular filtration rate (GFR) is a key marker of 
renal function, but direct measurement is invasive; in routine practice, equations are 
used for estimated GFR (eGFR) from serum creatinine. We systematically assessed 
bias and accuracy of commonly used eGFR equations in populations relevant to 
primary care.  
Content: MEDLINE, EMBASE and the Cochrane Library were searched for studies 
comparing measured GFR (mGFR) with eGFR in adult populations comparable to 
primary care and reporting both the Modification of Diet in Renal Disease (MDRD) 
and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations 
based on standardised creatinine measurements.  We pooled data on mean bias 
(difference between eGFR and mGFR) and on mean accuracy (proportion of eGFR 
within 30% of mGFR) using a random-effects inverse-variance weighted meta-
analysis. We included 48 studies of 26,875 patients that reported data on bias and/or 
accuracy. Meta-analysis of within-study comparisons where both formulae were 
tested on the same patient cohorts using isotope dilution-mass spectrometry-
traceable creatinine showed a lower mean bias in eGFR using CKD-EPI of 2.2 
ml/min/1.73m2 (95% CI 1.1 to 3.2; 30 studies; I2=74.4%) and a higher mean 
accuracy of CKD-EPI of 2.7% (1.6 to 3.8; 47 studies; I2=55.5%). Meta-regression 
showed that in both equations bias and accuracy favoured the CKD-EPI equation at 
higher mGFR values.  
Summary: Both equations underestimated mGFR but CKD-EPI gave more accurate 
estimates of GFR.  
4 
 
INTRODUCTION 1 
Chronic kidney disease (CKD) is associated with increased cardiovascular risk, 2 
progression to end stage renal failure and reduced survival (1, 2), and is increasing 3 
in prevalence globally (3). The majority of patients with CKD are managed in primary 4 
care in the UK (4), and, in the absence of interventions that can specifically reverse a 5 
decline in glomerular filtration rate (GFR) (5), management strategies address 6 
common risk factors for cardio-renal outcomes, such as hypertension and diabetes. 7 
Accurate identification of patients with CKD in primary care is therefore a key 8 
underpinning public health strategy to reduce the burden of disease associated with 9 
CKD.  10 
While no easy method for directly measuring GFR exists, various indirect formulae, 11 
including the Modification of Diet in Renal Disease  (MDRD) Study equation (6) and 12 
the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (7), 13 
provide estimated GFR (eGFR) based upon serum creatinine and other factors that 14 
influence creatinine production. These equations fulfil criteria important to a primary 15 
care setting: they both use a routinely available blood biomarker that can be sampled 16 
in primary care and require minimal additional patient level parameters. While 17 
alternative renal biomarkers such as cystatin C can be incorporated into eGFR 18 
equations (8) demonstrating improved correlation between eGFR and cardiovascular 19 
risk (9), the lack of availability of cystatin C in routine primary care limits the use of 20 
these equations in patients managed in the community.  21 
The performance of creatinine-based eGFR equations in populations relevant to 22 
primary care appears to vary. MDRD has been commonly used since 2000, but is 23 
known to underestimate GFR, particularly in the early stages of CKD (10), which are 24 
typically seen in primary care populations (11), and crucially around the cut point 25 
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between stages 2 and 3a, which in the UK determines entry onto a CKD primary 26 
care register and recommendations for routine annual monitoring (12).  By 27 
comparison, CKD-EPI has shown improved agreement between measured and 28 
estimated GFR, especially in the earlier stages of CKD (13), although this was 29 
validated in a pooled dataset comprising research study participants and specific 30 
clinical populations rather than patients representative of those seen in primary care. 31 
Nevertheless, national guidance on monitoring renal function in the UK (4) and the 32 
USA (5) has been updated to recommend estimating GFR using CKD-EPI instead of 33 
MDRD. 34 
There has been no reported systematic review and meta-analysis of studies that 35 
assess equation performance in populations specifically relevant to primary care, 36 
i.e., those with a lower prevalence of renal disease (and therefore higher mean 37 
eGFR) than the sets of individuals used for derivation and validation of routinely 38 
used formulae (11). We therefore systematically reviewed published studies 39 
comparing measured GFR (mGFR) with eGFR, calculated from both MDRD and 40 
CKD-EPI equations in populations relevant to a primary care setting.  41 
 42 
MATERIAL AND METHODS 43 
Data sources, searches and study selection 44 
MEDLINE, EMBASE and the Cochrane Library were searched from inception until 45 
23rd June 2017 for studies comparing mGFR using a reference method 46 
(radionuclide or iodinated tracers) with a simultaneous eGFR using the four variable 47 
MDRD formula and the CKD-EPI formula calculated from a creatinine assay 48 
standardized to isotope dilution-mass spectrometry methods. We included studies 49 
that recruited patients over 18 y of age in different healthcare settings; those not 50 
6 
 
recruiting primary care patients were assessed for similar mean age and renal 51 
function distributions to primary care populations (11). Studies recruiting highly 52 
selected patient populations not generalisable to primary care were excluded 53 
(transplanted organs, critical illness, single disorder case series) but not those 54 
prevalent in primary care, such as hypertension or diabetes. Studies were required 55 
to report either mean bias (mean difference between calculated eGFR and 56 
measured GFR) or accuracy (percentage of eGFR values within 30% of mGFR (P30) 57 
(4)). The search strategy is detailed in the online Supplemental Data file. A protocol 58 
for the systematic review was drafted for internal reference.  59 
Data extraction and quality assessment 60 
Two reviewers (JH, DL, JM, JV) independently selected abstracts for full text review 61 
and final inclusion, with any differences resolved by a third reviewer (CO’C, DL, EM). 62 
Two reviewers (JH, DL, JM, JV) extracted data in duplicate using a standardised 63 
data extraction form, with disagreement resolved by discussion and the third 64 
reviewer. Extracted items were mean bias, standard deviation (SD) or other measure 65 
of precision, accuracy, number of participants, recruitment setting, mean age, 66 
gender, co-morbid conditions and mean mGFR. Data on blood pressure, lipid 67 
concentrations, smoking status, body mass index and proteinuria were not extracted.  68 
Risk of bias was assessed using the revised tool for quality assessment of diagnostic 69 
studies (QUADAS-2) to assess bias and applicability of four domains: patient 70 
selection, index test, reference test, flow and timing (14). 71 
Data synthesis and analysis 72 
We present analyses of within-study comparisons of i) difference in bias between 73 
MDRD and CKD-EPI, in studies that compared both equations with mGFR and ii) 74 
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difference in accuracy between MDRD and CKD-EPI, both stratified into subgroups 75 
of high and low mGFR.  We also report meta-analyses of bias and accuracy 76 
separately for the MDRD equation and the CKD-EPI equation compared to mGFR.   77 
Difference in bias was calculated by taking the differences in mean absolute bias 78 
between eGFR using CKD-EPI and MDRD equations. A negative difference in bias 79 
represented lower bias using the CKD-EPI equation compared with the MDRD 80 
equation. Data on difference in bias between equations and mean bias for each 81 
equation were pooled using random-effects inverse-variance weighted meta-82 
analysis. If the SD could not be calculated from standard error or confidence 83 
intervals (CI), it was imputed by taking the mean SD from studies in which it could be 84 
calculated. We examined the impact of imputed SDs by conducting additional 85 
analyses which excluded studies where SDs could not be calculated.  86 
Difference in mean accuracy was calculated by taking the differences in accuracy 87 
between eGFR by subtracting MDRD accuracy from CKD-EPI accuracy. A negative 88 
accuracy therefore represented higher accuracy using the MDRD equation 89 
compared with the CKD-EPI equation. Data on difference in mean accuracy between 90 
equations and mean accuracy for each equation were pooled using random-effects 91 
inverse-variance weighted meta-analysis. Standard errors of the accuracy were 92 
calculated as square root of [proportion x (1 - proportion) / n]. Studies were ordered 93 
in forest plots by mean mGFR in the included patients (low to high). Subgroup 94 
analyses were used to compare low and high mGFR (< 60 ml/min/1.73m2, ≥ 60 95 
ml/min/1.73m2 respectively) for the difference in bias and difference in accuracy 96 
between MDRD and CKD-EPI.  97 
8 
 
Heterogeneity is reported using the I2 statistic (15).  High heterogeneity was 98 
investigated using random-effects meta-regression of each outcome separately 99 
against three pre-specified key parameters that differed between renal clinic 100 
populations and primary care populations: mGFR, age and gender.  101 
We assessed potential publication bias through sensitivity analyses excluding 102 
smaller studies (<100 participants).  103 
Analyses were carried out using Stata (StataCorp. Stata Statistical Software: 104 
Release 14.1. College Station, TX) using the commands metan (16) and metareg 105 
(16).   106 
 107 
RESULTS 108 
Fig. 1 summarises the process of identification and selection of studies. In total, 109 
9559 references were identified after duplicates were removed and 8030 were 110 
excluded after title and abstract review. Of the 1529 full-text articles that were 111 
reviewed, 182 studies reported eGFR but were excluded because they had no 112 
extractable data, did not use both MDRD and CKD-EPI equations, or did not use 113 
isotope dilution-mass spectrometry traceable assays.  These and other reasons for 114 
exclusion are shown in Fig. 1 (1481 excluded studies). Forty-eight studies of 26,875 115 
patients met all the inclusion criteria.  116 
Characteristics of the included studies are summarised in Table 1. Of the 48 117 
included studies, some studies separately reported data from multiple subgroups, 118 
resulting in 60 comparisons. Twenty-nine studies (31 comparisons) reported both 119 
mean bias and P30, one study reported mean bias only and 18 studies (29 120 
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comparisons) reported P30 only.  The mean age of participants across studies was 121 
57 y, 52% were male, and mean±SD mGFR was 71.5±23.5 ml/min/1.73m2.  122 
The methodological quality was assessed in all included studies; only three studies 123 
were considered as unclear in five or more of the areas for consideration. For the 124 
domains of ‘index test’ and ‘reference standard’ no studies were assessed as high 125 
risk of bias, two studies were assessed as high risk of bias for ‘flow and timing’ and 126 
for all three domains the majority of studies (>85%) were assessed as low risk and 127 
therefore high quality. The domain of ‘patient selection’ was variable and in almost 128 
half of the papers it was not possible to determine the degree of bias due to 129 
inadequate descriptions of recruitment processes (online Supplemental Table 1).  130 
Difference in bias between CKD-EPI and MDRD equations for eGFR 131 
Across the 30 studies of 7453 patients that reported mean bias, the difference in bias 132 
was 2.2 ml/min/1.73m2 (95% CI 1.1 to 3.2) lower in eGFR estimated using CKD-EPI 133 
than using MDRD (Fig. 2), but there was high heterogeneity between studies 134 
(I2=74.4%, p<0.0001). Sub-group analysis of low and high mGFR showed CKD-EPI 135 
had significantly lower bias than MDRD only for those studies with mean mGFR ≥ 60 136 
ml/min/1.73m2 (Fig. 2). Considering bias in the MDRD equation, eGFR on average, 137 
across all studies, was 4.7 ml/min/1.73m2 (95% CI 0.8 to 8.7) lower than mGFR, but 138 
varied between studies with high heterogeneity (I2=99.2%, p<0.0001). Bias in the 139 
CKD-EPI equation was on average lower than mGFR by 2.8 ml/min/1.73m2 (95% CI 140 
0.5 to 6.0) with variation between studies (I2=99.0, p<0.0001) (Fig. 3). Similar results 141 
were obtained in sensitivity analyses excluding one study (17) in which standard 142 
deviation was estimated or excluding studies with fewer than 100 participants (data 143 
not shown).    144 
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Difference in accuracy between CKD-EPI and MDRD equations for eGFR 145 
Accuracy estimates for both formulae were reported in 47 studies of 26,358 patients. 146 
In a meta-analysis, mean accuracy of CKD-EPI was 2.7% higher than MDRD (95% 147 
CI 1.6 to 3.8) with moderate heterogeneity across studies (I2=55.5%, p<0.0001) (Fig. 148 
4). Sub group analysis of low and high mGFR showed CKD-EPI had significantly 149 
higher accuracy than MDRD only for those studies with mean mGFR ≥ 60 150 
ml/min/1.73m2. Mean accuracy of MDRD equation was 74% (95% CI 71 to 77) with 151 
high heterogeneity (I2=97.8%, p<0.0001) whereas mean accuracy of the CKD-EPI 152 
equation was 77% (95% CI 74 to 80) again with high heterogeneity (I2=98.6%, 153 
p<0.0001) (Fig. 5). Similar results were obtained in sensitivity analyses excluding 154 
studies with fewer than 100 participants (data not shown). 155 
Relationship of bias and accuracy to renal function in each study 156 
In meta-regression analyses, difference in bias between equations increased with 157 
increasing mGFR. Thus for each 10 ml/min/1.73m2 increase in mGFR the difference 158 
in bias increased by 0.8 ml/min/1.73m2 (0.3 to 1.3; p=0.002). Difference in accuracy 159 
between equations increased in favour of CKD-EPI with increasing mGFR. For each 160 
10 ml/min/1.73m2 increase in study mean mGFR, the difference in accuracy (P30) 161 
increased by an additional 0.9% (0.4 to 1.5; p=0.001) (Supplemental Fig. 1). 162 
No association was found between mean bias of the MDRD equation and increasing 163 
mean mGFR using meta-regression (p=0.325). MDRD mean accuracy increased 164 
with mean mGFR. For each 10 ml/min/1.73m2 increase in study mean mGFR, the 165 
accuracy (P30) of eGFR increased by an additional 2.5% (1.1 to 3.9; p=0.001) (Data 166 
not shown). Neither bias nor accuracy were associated with mean patient age 167 
(p=0.975, p=0.382 respectively) or the proportion of men (p=0.63, p=0.894 168 
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respectively), and we found no factor that reduced the I2 statistics for heterogeneity 169 
by more than 5%.  170 
No association was found between mean bias of the CKD-EPI equation and 171 
increasing mean mGFR using meta-regression (p=0.594). CKD-EPI mean accuracy 172 
increased with mean mGFR. For each 10 ml/min/1.73m2 increase in study mean 173 
mGFR, the accuracy (P30) of eGFR increased by an additional 3.6% (2.4 to 4.9; 174 
p<0.0001) (Data not shown). Neither bias nor accuracy were associated with patient 175 
age (p=0.476, p=0.291 respectively) or the proportion of men in the study (p=0.983, 176 
p=0.744 respectively), and no factor reduced the I2 statistics for heterogeneity by 177 
more than 5%. 178 
DISCUSSION 179 
In populations relevant to primary care, we found that both the MDRD and CKD-EPI 180 
equations underestimated GFR, but that estimates from CKD-EPI were slightly more 181 
accurate than those from MDRD. Clinical and statistical heterogeneity between 182 
studies was high. In studies with lower mean levels of renal function (mGFR < 60 183 
ml/min/1.73m2) eGFR was no different whether using CKD-EPI or MDRD. However, 184 
at higher levels of renal function CKD-EPI performed better than MDRD both in 185 
terms of bias and accuracy.  Therefore, given the distribution of renal function seen 186 
in primary care patients (11), this study supports the recent decision in national 187 
guidelines to estimate GFR using the CKD-EPI equation (4).  188 
Our analysis shows that absolute bias is smaller in CKD-EPI than MDRD; however, it 189 
varies in both direction and magnitude between studies (high statistical 190 
heterogeneity for both mean absolute bias and mean bias).  191 
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Bias alone is not a straightforward indicator of accurate estimation of GFR, because 192 
high variability can cause poor accuracy even when bias is low.  Therefore, our 193 
analyses of accuracy (P30) are potentially more indicative of overall usefulness of the 194 
two equations.  On this metric too, CKD-EPI performs better than MDRD, but the 195 
mean effect is small compared to the variation between studies. 196 
Both the MDRD and CKD-EPI equations estimate GFR using the same variables 197 
(age, gender, ethnicity and serum creatinine), but there were large differences in the 198 
distribution of renal function in the populations from which they were derived. The 199 
MDRD study population had CKD and a mean GFR of 40 mL/min/1.73m2,(6) while 200 
the CKD-EPI study population included subjects with and without CKD who had a 201 
mean GFR of 68 mL/min/1.73m2 (7).  Differences in non-renal determinants of serum 202 
creatinine, such as muscle mass and diet, are likely to contribute to the differences in 203 
equation performance seen across the range of renal function (18), as may the 204 
analytical techniques used to measure serum creatinine. Our results are consistent 205 
with a smaller systematic review (18). A further study reported that while CKD-EPI 206 
has slightly better performance, assessed using bias and accuracy, the differences 207 
were not clinically significant, other than bias at very low levels of renal function (19).   208 
Further improvement in estimating renal function is, however, needed. Guidelines 209 
suggest that the proportion of eGFR measurements within 30% of mGFR should 210 
exceed 90% (20), yet accuracy within studies was rarely this high. Given that 211 
creatinine measurements have high levels of laboratory and biological variability (5, 212 
21), alternative filtration markers, such as cystatin C, that are less dependent on 213 
muscle mass, may give better estimates of GFR, and have been included in UK 214 
guidelines for a more secure early stage diagnosis of CKD (4).  While measured 215 
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GFR is sometimes used in clinical practice when a high degree of precision is 216 
required (22, 23), it is not a practical solution at population level in primary care.  217 
This is the most comprehensive systematic review and meta-analysis to examine the 218 
accuracy of MDRD and CKD-EPI, by comparing eGFR with mGFR, in populations 219 
where relevance to primary care has been assessed. While the majority of studies 220 
did not clearly recruit from community settings, we used mean study mGFR to 221 
construct meta-regressions that estimate bias and accuracy at the higher levels of 222 
renal function seen in primary care populations. We used broad inclusion criteria, 223 
including all studies that compared eGFRs derived from MDRD or CKD-EPI with 224 
mGFR. A smaller previous review only presented descriptive results and restricted 225 
inclusion to larger studies comparing eGFRs derived from two or more equations 226 
with mGFR (18),  While this means we have included smaller studies, sensitivity 227 
analyses excluding those with fewer than 100 participants, to investigate publication 228 
bias, gave similar results. Furthermore, effects were tested at the study level rather 229 
than individual level. 230 
The quality of patient selection in included studies was variable; in many studies the 231 
generalisability of individual studies was unclear due to recruitment methods. 232 
Different reference tests for mGFR were used and the effect of this on equation 233 
performance is not known. The high clinical and statistical heterogeneity requires 234 
caution in the interpretation of specific numerical results, such as the estimates of 235 
mean bias and mean accuracy for each equation.  However, there is a direct link 236 
between meta-analysis size and detected heterogeneity (24) and the within-study 237 
analysis of difference in accuracy supports the interpretation that CKD-EPI can be 238 
more accurate than MDRD. Additionally, some large studies reported metrics that 239 
were not analysable, such as median bias or mean % difference, and could therefore 240 
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not be included in the meta-analysis. If these studies reported a smaller bias or 241 
accuracy, then our meta-analyses could be overestimating the effect sizes.  242 
In summary, CKD-EPI gave more accurate estimates of mGFR particularly in 243 
populations with higher mGFR (better renal function), such as those seen in primary 244 
care. However, continued investigation of improved estimating equations, novel 245 
biomarkers, or both, are merited to optimise CKD detection and monitoring.  246 
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 497 
Table 1. Characteristics of studies using both MDRD and CKD-EPI and IDMS-498 
traceable assays  499 
Author Year N Recruitment 
setting 
Population mGFR Age, y % Male Reported 
Altiparmak (25) 2013 229 Renal mix 45.6 53.9 49 Mean bias 
P30 
Arreola-Guerra 
(26) 
2014 97 NR healthy 102.7 35.8 58.8 Mean bias 
P30 
Bevc (27)  2012A 255 Renal mix 55.5 59.7 53.7 Mean bias 
P30 
Bevc (28) 2012 113 Renal mix 42.9 64 61.9 Mean bias 
P30 
Bhuvanakrishna 
(29) 
2015 508 Potential 
donor 
healthy 91.7 44.1 48 P30 
Bjork (30) 2011 850 Other mix 55 60 55.8 P30 
Bjork (31) 2012 996 Other healthy 44 61 56.1 P30 
Bouquegneau 
(32) 
2013 366 Other mix 56 55 49.5 Mean bias 
P30 
Camargo (33)  2011 55 Other healthy 98 58 49 Mean bias 
P30 
Camargo (33) 2011 56 Other diabetes 106 58 49 Mean bias 
P30 
Chen (34) 2014 139 Hospital mix 68.8 51 51 P30 
Chung (35) 2013 207 Potential 
donor 
healthy 116.3 40.4 42 Mean bias 
P30 
Craig (36, 37) 2011 516 Other mix 65 61 54 Mean bias 
Cvan (38) 2015 43 Other CHF 53.1 73 58 Mean bias 
P30 
Du (39) 2011 142 Other renal 41.77 65.2 59.9 Mean bias 
P30 
Eriksen (40) 2010 1621 Primary Care healthy 91.7 56.9 49.3 P30 
Flamant (41) 2012 782 Other renal 42.6 72.8 65.2 P30 
Hu (42) 2013 17 Potential 
donor 
healthy  47 75 Mean bias 
P30 
Iliadis (43) 2011 448 Diabetes diabetes 72 65 47 Mean bias 
P30 
Jeong (44) 2013 607 Other mix NR NR NR Mean bias 
P30 
Jessani (45) 2014 581 Primary Care mix 91 50.6 50.3 P30 
Kilbride  (46) 2013 394 Primary Care mix NR 80 48 P30 
Kong (47) 2013 977 Renal mix 68.3 48.3 49 Mean bias 
P30 
Koppe (48) 2013 224 Renal mix 41.3 75.3 57.1 P30 
Krones (49) 2015 24 Potential 
donor 
healthy 97.5 51 25 Mean bias 
P30 
Lemoine (17) 2013 218 Other mix 51.8  57.8 P30 
Levey (7) 2009 3896 Renal healthy 68 50 55 P30 
Liu (50) 2013 332 Renal renal 39.7 70 62 Mean bias 
P30 
Lui (51) 2014A 209 Hospital diabetes 47.9 61.6 57.4 Mean bias 
P30 
Lui (52) 2014 351 Hospital non-diabetes 60.7 58.3 59.5 P30 
Lui (52) 2014 351 Hospital diabetes 62.8 60.3 59.3 P30 
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Lui (52) 2014 210 Hospital diabetes    P30 
Lopes (53) 2013 95 Other healthy 55 85.3 30 Mean bias 
P30 
Lujan (54) 2012 85 Potential 
donor 
healthy 116 41 45.9 Mean bias 
P30 
MacIsaac (55) 2015 199 Diabetes diabetes 80 62.8 67 Mean bias 
P30 
Maple-Brown (56) 2014 224 Other diabetes 97 52 37 P30 
Maple-Brown (56) 2014 340 Other non-diabetes 108 40 39 P30 
Michels (57) 2010 271 Primary Care mix 72.6 44.3 44 Mean bias 
P30 
Murata (58) 2011 583 Other healthy 98.9 56.1 55 P30 
Murata (58) 2011 2324 Other renal 98.9 56.1 55 P30 
Nyman (59) 2011 850 Other healthy 55 60 56 P30 
Nyman (60) 2014       P30 
Obiols (61) 2013 100 Other mix 90 53.6 55 Mean bias 
P30 
Praditpornsilpa 
(62) 
2011 350 Other renal 55.86 59.5 44.9 Mean bias 
P30 
Qiu (63) 2013 176 Other renal 40.7 48.8 51.6 Mean bias 
P30 
Sagou (64) 2016 120 Other healthy 100 34 50 Mean bias 
P30 
Schaeffner (65) 2012 570 Primary Care mix 60.4 78.5 57.2 Mean bias 
P30 
Silveiro (66) 2011 105 Diabetes diabetes 103 57 50 Mean bias 
P30 
Spithoven (67) 2013 336 Renal healthy 97.7 53.1 48 Mean bias 
P30 
Tent (68) 2010 253 Potential 
donor 
healthy 103 49.5 43 P30 
Teo (69) 2010 232 Renal renal 51.7 58.4 52 P30 
Valente (70) 2014 120 Hospital CHF 74 59 80 Mean bias 
P30 
Veronese (71) 2014 354 Other mix 87 53 45 Mean bias 
P30 
NR: Not reported  500 
 501 
 502 
 503 
 504 
 505 
 506 
 507 
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Figure1. Study flow chart. 508 
 509 
Figure 2. Difference in mean bias from CKD-EPI and mean bias from MDRD, and 510 
pooled estimate (diamond) stratified into subgroups of high and low mGFR using 511 
random effects meta-analysis  512 
Horizontal bars and diamond width denote 95% CIs, and box sizes indicate relative weight in the analysis 
513 
 514 
Figure 3. Mean bias between eGFR and mGFR calculated using MDRD (left) and 515 
CKD-EPI (right) equations, stratified into subgroups of high and low mGFR using 516 
random effects meta-analysis 517 
Horizontal bars and diamond width denote 95% CIs, and box sizes indicate relative weight in the analysis 
518 
 519 
Figure 4. Difference in mean accuracy from CKD-EPI and mean accuracy from 520 
MDRD, and pooled estimate (diamond) stratified into subgroups of high and low 521 
mGFR using random effects meta-analysis. (P30 – proportion of eGFR results within 522 
30% of mGFR result) 523 
Horizontal bars and diamond width denote 95% CIs, and box sizes indicate relative weight in the analysis 524 
 525 
 526 
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Figure 5. Mean accuracy between eGFR and mGFR calculated using MDRD (left) 527 
and CKD-EPI (right) equations, stratified into subgroups of high and low mGFR using 528 
random effects meta-analysis 529 
Horizontal bars and diamond width denote 95% CIs, and box sizes indicate relative weight in the analysis 
530 
